CytomX Therapeutics, Inc.'s ADC candidate, CX-2051, shows promise in colorectal cancer. Click here to read an analysis of ...

Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections RAICHUR, India, Nov ...

Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 – $2.0 billion Improves 2025 expected GAAP operating ...

Q3 2025 Management View CEO Linda Marbán highlighted the imminent top line readout from the HOPE-3 Phase III clinical study of deramiocel for Duchenne muscular dystrophy, stating this is "just weeks ...

In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...

The study tested ivonescimab, an innovative bispecific antibody, combining it with platinum-doublet chemotherapy in patients ...

A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.

Akebia Therapeutics shares retreated Monday after the company dropped plans for a Phase 3 clinical trial of its drug Vafseo for certain patients. Shares were trading at $1.66, down 19% and nearing the ...

Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 9:00 ...

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

SpyGlass Pharma has released positive data from 2 trials of its lead candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL ...